Birmingham, West Midlands -- (SBWIRE) -- 12/05/2013 -- Value Penny Stocks issues special report on McEwen Mining Inc (NYSE:MUX), Polycom Inc (NASDAQ:PLCM), Immunomedics, Inc. (NASDAQ:IMMU), Clovis Oncology Inc (NASDAQ:CLVS).
McEwen Mining Inc (NYSE:MUX) opened its last trade at the price of $1.81. Its closing price was $1.89 after gaining 6.18% for the day. The company traded with the total volume of 2,192,131 shares, while its average trading volume remained 2.31 million shares. The beta of this stock stands at -0.27. McEwen Mining Inc. engages in the exploration for, development of, production, and sale of gold, silver, and copper. The company’s principal assets consist of a 49% interest in the San José Mine in Santa Cruz, Argentina; the El Gallo complex in Sinaloa, Mexico; the Gold Bar Project in Nevada, United States.
For How Long MUX will Fight for Profitability? Read This Trend Analysis report
Polycom Inc (NASDAQ:PLCM) percentage change surged 2.08% to close at $10.80 with the total traded volume of 2,184,381 shares, along with average volume of 4.99 million shares. The 52 week range of the stock remained $9.00 - $11.94, while its day lowest price was $10.62. The share price hit the day highest price of $10.88. Polycom, Inc. provides standards-based unified communications and collaboration (UC&C) solutions for voice and video collaboration. The company offers video, voice, and content-management and content-sharing solutions, such as telepresence and conference room systems, home/work office solutions, applications for mobile devices, browser-based video collaboration, cloud-delivered services, and specialized healthcare video carts.
For How Long PLCM’s Gloss will Attract Investors? Find out via this report
Immunomedics, Inc. (NASDAQ:IMMU) traded on volume of 2,172,075 shares in the last session against average volume of 1.24 million shares. The company started its trading session with the price of $4.65 and closed at $4.71 by scoring 6.56%. Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases.
Will IMMU Continue To Move Higher? Find Out Here
Clovis Oncology Inc (NASDAQ:CLVS) started its last trading session with the price of $56.85 and closed at $55.99 by scoring -5.02%. The stock traded with total volume of 2,101,552 shares, while the average trading volume remained 397,124.00 shares. Day range for the stock was $55.11 - $58.95. Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway.
Will CLVS Get Buyers Even After The Recent Rally? Find Out Here
About Value Penny Stocks:
Value Penny Stocks was made by Two Active traders, Steve and Wilson, whom have made a platform for traders in order to provide traders the #1 Penny Stock Newsletter which actually gives value to your money and makes your portfolio full of profits. We concentrate on small cap stocks that trade on NYSE, NASD, AMEX, OTCBB, and OTC exchanges. These are usually stocks that will trade under $5 a share and offer the utmost potential profit on your short or long term investment. We also devote ourselves to understanding the overall market situations and use this knowledge in order to gain a better perception during our stock picking decisions.
We at ValuePennyStocks.com are engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Please Read Our Full Disclaimer at: http://www.valuepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)